Novartis Ag (NVSEF) Accumulated Expenses (2017 - 2025)

Novartis Ag has disclosed Accumulated Expenses across 9 years of filings, most recently posting $1.0 billion for Q4 2025.

• Accumulated Expenses for Q4 2025 came in at $1.0 billion, up 518.34% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.0 billion (up 518.34% YoY), and the FY2025 annual result was $1.0 billion, up 518.34% from the prior year.
• Accumulated Expenses came in at $1.0 billion for Q4 2025 at Novartis Ag, up from $169.0 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $1.1 billion in Q4 2022 to a low of $116.0 million in Q4 2023.
• The 5-year median for Accumulated Expenses is $169.0 million (2024), against an average of $503.2 million.
• Across the five-year window, Accumulated Expenses surged 733.86% in 2022 and plunged 89.05% in 2023, its largest moves.
• Novartis Ag's Accumulated Expenses stood at $127.0 million in 2021, then jumped by 733.86% to $1.1 billion in 2022, then slumped by 89.05% to $116.0 million in 2023, then soared by 45.69% to $169.0 million in 2024, then surged by 518.34% to $1.0 billion in 2025.
• The last three Accumulated Expenses figures came in at $1.0 billion (Q4 2025), $169.0 million (Q4 2024), and $116.0 million (Q4 2023), per Business Quant data.